Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026

Bright Minds Biosciences (NASDAQ:DRUG) will report topline Phase 2 results for BMB-101 on January 6, 2026 at 8:00 AM ET.

Rhea-AI Summary

Bright Minds Biosciences (NASDAQ:DRUG) will report topline Phase 2 results for BMB-101 on January 6, 2026 at 8:00 AM ET. The company said the announcement covers patients with drug-resistant absence seizures and developmental and epileptic encephalopathy.

A live conference call and webcast will present the data, include a discussion and a Q&A session, and a replay will be posted in the company’s Investors > Events and Presentations section after the event. Participants can submit questions using the webcast "Questions" tab.

Argus Jan 6 session

+16.50% close to close Open Argus

Details

News Market Reaction – DRUG

In the Jan 6 session, DRUG gained 16.50%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +16.5% in the session following this news. A strong positive reaction aligns with D...

Analysis

The stock surged +16.5% in the session following this news. A strong positive reaction aligns with DRUG’s history of favorable responses to pipeline milestones, where prior clinical and program updates saw one-day gains up to 7.55%. The move followed confirmation of a January 6, 2026 topline readout for the BMB-101 Phase 2 trial in drug-resistant absence seizures and developmental and epileptic encephalopathies. Investors evaluating sustainability could watch actual efficacy and safety data relative to earlier preclinical and program signals.

Key Figures

NOVA trial duration: 16 weeks NOVA extension: 9 months Male efficacy 1h: 86% vs 81% +5 more

NOVA trial duration

16 weeks

Phase 2a NOVA study of BMB-101 in Prader-Willi syndrome

NOVA extension

9 months

Optional open-label extension for NOVA Phase 2a study

Male efficacy 1h

86% vs 81%

BMB-201 vs sumatriptan in male rats at 1 hour

Male efficacy 2h

53–64% vs 44%

BMB-201 vs sumatriptan in male rats at 2 hours

Female efficacy 1h

76–100% vs 56%

BMB-201 vs sumatriptan in female rats at 1 hour

Female efficacy 2h

80% vs 63%

BMB-201 vs sumatriptan in female rats at 2 hours

Janus Henderson stake

1,145,660 shares (16.3%)

Schedule 13G/A filing dated Aug 14, 2025

Sio Capital stake

512,338 shares (7.27%)

Schedule 13G/A filing dated Aug 13, 2025

Historical Context

5 past events · Latest: Nov 25

5 events

1. Nov 25

   Conference appearances

   24h Move

   +1.0%

   Highlighted 5-HT2 agonist work at major December 2025 healthcare and epilepsy meetings.

2. Nov 17

   Advisory board expansion

   24h Move

   +0.2%

   Added PWS experts to advisory board supporting BMB-101 and BMB-105 development.

3. Nov 06

   Program initiation

   24h Move

   +7.5%

   Launched PWS program, NOVA Phase 2a BMB-101 study, and BMB-105 Phase 1 plans.

4. Oct 30

   Conference and options

   24h Move

   +0.5%

   Outlined November 2025 conference talks and granted director and officer stock options.

5. Sep 04

   Preclinical results

   24h Move

   +1.6%

   Reported BMB-201 outperformed sumatriptan in a validated preclinical headache model.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase 2, developmental and epileptic encephalopathy, 5-ht receptor agonists

3 terms

phase 2 medical

"to report topline results for the Phase 2 trial of BMB-101 in patients"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

developmental and epileptic encephalopathy medical

"drug-resistant Absence Seizures and Developmental and Epileptic Encephalopathy."

A severe neurological condition that begins in infancy or early childhood, marked by frequent, hard-to-control seizures and slowing or loss of normal development such as movement, learning and communication. Think of it as a critical control system in a child’s brain that malfunctions and interferes with growth and daily function. For investors it signals a high unmet medical need, focused regulatory attention and the potential for significant commercial value — but also greater clinical and development risk for therapies.

5-ht receptor agonists medical

"developing highly selective 5-HT receptor agonists for neurological and psychiatric disorders"

5-HT receptor agonists are drugs that bind to and activate specific serotonin receptors in the brain and body, essentially turning on signals that serotonin normally controls. Like flipping a particular light switch to change how a room behaves, these medicines can alter mood, pain perception, digestion or blood vessel tone; investors track them because clinical trial results, regulatory approvals and market demand directly affect a drug developer’s revenue prospects and stock value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

– Conference Call and Live Webcast at 8AM ET –

NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (Nasdaq: DRUG) (“Bright Minds” or the “Company”), a clinical-stage biotechnology company focused on developing highly selective 5-HT receptor agonists for neurological and psychiatric disorders, today announced that it will host a conference call and live webcast at 8:00AM ET on January 6, 2026, to report topline results for the Phase 2 trial of BMB-101 in patients with drug-resistant Absence Seizures and Developmental and Epileptic Encephalopathy.

Webcast Information

The Bright Minds virtual event will be webcast live and a replay will be available after the event by visiting the “Investors” section of the Company’s website and selecting “Events and Presentations.”

Date and Time: January 6, 2026, 8AM ET
Webcast: https://app.livestorm.co/bright-minds-biosciences/bmb-101-topline-data-announcement

The call will include a discussion of the data followed by a Q&A session. Individuals who wish to ask questions should use the “Questions” tab available during the live webcast.​

About Bright Minds Biosciences
Bright Minds is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including Rare Epilepsy, Prader-Willi Syndrome, Depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients' lives.

Bright Minds has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.​

Contact
Alex Vasilkevich
Chief Operating Officer
Bright Minds Biosciences Inc.
T: 414-731-6422
E: alex@brightmindsbio.com

Investor Relations
Lisa M. Wilson
T: 212-452-2793
E: lwilson@investorrelations.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Bright Minds (DRUG) release BMB-101 Phase 2 topline results?

Topline results will be announced on January 6, 2026 at 8:00 AM ET.

What conditions are included in the BMB-101 Phase 2 announcement for DRUG?

The announcement covers drug-resistant absence seizures and developmental and epileptic encephalopathy.

How can investors join the Bright Minds (DRUG) webcast for the BMB-101 topline data?

Join the live webcast via the provided link at 8:00 AM ET on January 6, 2026 and use the "Questions" tab to ask questions.

Will Bright Minds (DRUG) make a replay of the BMB-101 presentation available?

Yes. A replay will be available after the event in the company’s Investors > Events and Presentations section.

Will the BMB-101 webcast include a Q&A session for analysts and investors?

Yes. The call will include a discussion of the data followed by a Q&A session where participants can ask questions via the webcast.

Where is the Bright Minds (DRUG) BMB-101 webcast hosted online?

The webcast is hosted at the company’s livestream page: https://app.livestorm.co/bright-minds-biosciences/bmb-101-topline-data-announcement.